Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 15.4% in March

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,100 shares, a decline of 15.4% from the February 28th total of 1,300 shares. Based on an average daily volume of 15,900 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

Addex Therapeutics Trading Down 8.8 %

NASDAQ ADXN opened at $7.34 on Tuesday. Addex Therapeutics has a 12 month low of $6.67 and a 12 month high of $27.90. The stock has a 50-day simple moving average of $7.70 and a 200 day simple moving average of $8.54. The company has a market capitalization of $7.78 million, a PE ratio of -21.59 and a beta of 1.76.

Institutional Trading of Addex Therapeutics

A hedge fund recently bought a new stake in Addex Therapeutics stock. Citadel Advisors LLC acquired a new stake in shares of Addex Therapeutics Ltd (NASDAQ:ADXN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 1.14% of Addex Therapeutics as of its most recent filing with the Securities & Exchange Commission. 16.14% of the stock is currently owned by institutional investors.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.